Recruiting
Phase 1
Phase 2

Deferasirox, Deferoxamine, Combination

Sponsor:

Weill Medical College of Cornell University

Code:

NCT00738413

Conditions

Thalassemia

Eligibility Criteria

Sex: All

Age: 18 - 50

Healthy Volunteers: Not accepted

Interventions

Deferoxamine

Deferasirox

Study Details

Brief summary:

Subjects with thalassemia major require regular transfusion therapy to sustain life. The iron present in the transfused blood remains in the body where it can cause a variety of organ dysfunctions. Lifelong iron chelation therapy is needed to maintain iron balance but its effectiveness varies greatly. Like that of deferoxamine (Desferal, DFO) the mainstay of chelation therapy for 30 years, the effectiveness of deferasirox (Exjade, ICL670), the newly approved, orally effective iron chelating drug, is not satisfactory in all subjects. Even with good compliance, the iron excretion induced by a given drug exhibits wide subject-to-subject variability. There is often persistent iron overload of extra hepatic tissues such as the heart and pancreas leading to cardiac disease and diabetes. Combining the drugs may be a better approach in those subjects at increased risk. The iron balance studies proposed will permit an assessment of the potential of such a combination to place subjects in net negative iron balance and the relative effectiveness of the combination in relation to that of the individual drugs, an additive effect being expected. With such information, physicians will be able to design individualized chelation regimens that maximize effectiveness while minimizing side effects by adjusting the ratio and/or the dosing schedule of the two drugs.

Conditions

Thalassemia

Study ID

NCT00738413

Start date

Aug, 2008

Status verified date

Nov, 2010

Completion date

Dec, 2009

Anticipated

Primary completion date

Sep, 2009

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 50

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subjects with transfusional iron overload secondary to thalassemia major, aged 18 or older, may participate after giving written informed consent. Subjects must have no clinically significant finding in their medical history, on physical examination or as a result of laboratory assessments other than those consistent with thalassemia major and its complications, such as compensated cirrhosis, endocrine insufficiency and diabetes.
  • Subjects must have a serum ferritin greater than 1000 ng/mL, a platelet count greater than 100,000/mm3, and a serum creatinine within the normal range.
  • Subjects must be willing and able to discontinue their usual regimen of DFO, deferiprone (L1, Ferriprox) or Exjade for the duration of the study.
  • A woman of childbearing potential must have a negative serum pregnancy test at screening. She must use a medically acceptable form of birth control during the study and for 1 month afterward. Acceptable birth control measures include: abstinence, oral contraceptives, hormonal contraceptive implants, barrier contraceptives (condom, diaphragm with spermicide), IUD, and/or a vasectomized partner. Male subjects must also use barrier contraceptives during the study and for 1 month thereafter.
  • The subjects must also have a level of understanding and willingness to cooperate with the confinement and procedures described in the consent form and scheduled by the study site. In addition, he/she must be able to provide voluntary written informed consent.
  • Subjects must weigh at least 40 kg.

Exclusion Criteria:

  • Subjects can not have a history of clinically significant gastrointestinal, renal, hepatic, endocrine, oncologic, infectious, pulmonary or cardiovascular disease, other than conditions associated with thalassemia and iron overload, such as compensated cirrhosis, endocrine insufficiency and diabetes, or a history of tuberculosis, epilepsy, psychosis, glaucoma or any other condition, which in the opinion of the investigators, would jeopardize the safety of the subject or impact the validity of the study results.
  • Subjects can not be HIV positive or have active HCV.
  • A history of serious immunologic hypersensitivity to any medication, such as anaphylaxis or angioedema.
  • Participation in a previous investigational drug study within the 30 days preceding screening. A chelation regimen including deferiprone or Exjade within 30 days of screening would not exclude subjects coming from regions where these drugs are an approved medication.
  • Women who are pregnant, or breast-feeding.
  • Current alcohol or drug abuse.
  • An inability to adhere to the designated procedures and restrictions of this protocol.
  • Subjects with abnormal or irregular bowel function (defined as more than 3 bowel movements/day or less than 1 bowel movement every other day).
  • Subjects receiving warfarin, digoxin, or anti-arrhythmic or anti-seizure medications.
  • Subjects with a known allergy to Exjade or DFO that prevents chronic administration.

Study Design

Enrollment

6 participants

Anticipated

Allocation

Non randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Arm 1

Subjects will be treated for 6 days with deferoxamine.

active comparator: Arm 2

Subjects will be treated for 6 days with deferasirox.

experimental: Arm 3

Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.

Interventions

Deferoxamine

Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.

Deferasirox

Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.

Primary outcome measure

  • The primary outcome measure is to assess the safety and tolerability of combining DFO and deferasirox in thalassemia subjects with translation iron overload. [ Time Frame: 34 days ]

Central Contacts and Locations

Central contacts

Robert W Grady, Ph.D.

212-746-3422rwgrady@med.cornell.edu

Patricia J Giardina, M.D.

212-746-3415pjgiard@med.cornell.edu

Locations

Weill Cornell Medical Center

Recruiting

New York, New York, United States, 10021

Contacts

Robert W Grady, Ph.D.

212-746-3422rwgrady@med.cornell.edu

Kristen Muirhead, BS

212-746-3264krm2066@med.cornell.edu

Principal Investigator:

Robert W Grady, Ph.D.

More Information

Sponsor

Weill Medical College of Cornell University

Last update posted

Nov 5, 2010

Last verified

Nov, 2010

Keywords

  • Iron chelation
  • Iron balance
  • Secondary iron overload
  • deferoxamine
  • deferasirox

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2010-11-05.